Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. Leighl NB, et al. Among authors: steinberg j. Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8. Clin Lung Cancer. 2017. PMID: 27686971 Free PMC article. Clinical Trial.
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A, Kaye S, Van Tornout J, Sessa C, Gore M, Naumann RW, Hirte H, Colombo N, Chen J, Gorla S, Poondru S, Singh M, Steinberg J, Yuen G, Banerjee S. Oza A, et al. Among authors: steinberg j. Gynecol Oncol. 2018 May;149(2):275-282. doi: 10.1016/j.ygyno.2018.01.019. Epub 2018 Feb 14. Gynecol Oncol. 2018. PMID: 29454514 Free article. Clinical Trial.
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O'Brien T, Kelly CM, Winer E, Yardley DA. Krop I, et al. Among authors: steinberg j. Clin Cancer Res. 2020 Dec 1;26(23):6149-6157. doi: 10.1158/1078-0432.CCR-20-1693. Epub 2020 Sep 28. Clin Cancer Res. 2020. PMID: 32988969 Clinical Trial.
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC. Wong CI, et al. Among authors: steinberg j. J Clin Oncol. 2009 Oct 1;27(28):4718-26. doi: 10.1200/JCO.2008.21.7125. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720910 Clinical Trial.
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Traina TA, et al. Among authors: steinberg j. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.
1,600 results